Tengion, Inc.  

(Public, OTCMKTS:TNGNQ)   Watch this stock  
Find more results for NASDAQ:TNGN
0.00000 (0.00%)
Feb 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.00
Open     -
Vol / Avg. 0.00/17,008.00
Mkt cap 55,287.00
P/E     -
Div/yield     -
EPS -2.41
Shares 36.62M
Beta 26.75
Inst. own 12%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -618.10% -99.20%
Return on average equity - -
Employees 25 -
CDP Score - -


3929 Westpoint Blvd Ste G
WINSTON SALEM, NC 27103-6761
United States - Map
+1-336-7225855 (Phone)
+1-302-6555049 (Fax)

Website links


Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells. The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.

Officers and directors

David I. Scheer Independent Chairman of the Board
Age: 63
Carl-Johan Dalsgaard M.D. Independent Director
Age: 56
Diane K. Jorkasky M.D. Independent Director
Age: 61
Richard E. Kuntz M.D. Independent Director
Age: 58
Lorin Jeffry Randall Independent Director